Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Boehringer Ingelheim and LEO Pharma partner to advance spesolimab for generalized pustular psoriasis.
Jul 14, 2025•11 months ago
Contract Type
partnership
Ingelheim am RheinPharmaceuticalpharmaceuticalsDescription
Boehringer Ingelheim and LEO Pharma have entered into a partnership for the global development and commercialization of spesolimab. This agreement aims to enhance access to the treatment for patients with generalized pustular psoriasis, involving a €90 million upfront payment along with future milestone payments.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months